Kinloch Capital’s Amgen AMGN Stock Holding History

Kinloch Capital’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-172	Closed	-$40K	–	70
2020 Q4	$40K	Buy	+172	New	+$39.7K	0.03%	117

Other funds holding AMGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Kinloch Capital's AMGN Position: Q1 2021 in Review

Kinloch Capital sold out of Amgen (AMGN) in Q1 2021, closing a stake of 172 shares — an estimated $40K sold.

Kinloch Capital first reported a position in AMGN in Q4 2020 and held it in 1 quarter. The position peaked at $40K in Q4 2020. 2,218 funds tracked by Wall St. Rank hold AMGN as of Q1 2021.

Kinloch Capital reported no remaining Amgen position as of Q1 2021 after selling out during the quarter.
Kinloch Capital sold 172 Amgen shares in Q1 2021, an estimated $40K.
Kinloch Capital first reported a position in Amgen in Q4 2020 and held it in 1 quarter.
Kinloch Capital's Amgen position peaked at $40K in Q4 2020.
2,218 funds tracked by Wall St. Rank held Amgen as of Q1 2021.

Based on Kinloch Capital's 13F filing for Q1 2021, filed 11 May 2021.